SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors 24-month HOPE-3 extension data for investigational Duchenne therapy deramiocel, presented at the World Muscle Society congress, showed slower upper-limb decline among patients who switched from placebo, drawing attention to the stock. Traders largely view the findings as supportive ahead of the FDAs November review, while debate continues over the datas statistical interpretation and whether it will change the agencys decision.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCNs sharp rally and apparent resistance breakout are driving attention, with traders anticipating further gains while others warn the move may fade. Some link the strength to Zebecs payroll and card expansion or speculate about Robinhood and BlackRock involvement, but those rumored connections are unconfirmed.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera is drawing attention after positive Phase 2 results for ABCL635, its investigational menopause treatment, with traders focused on a fuller data presentation and the drugs potential path toward Phase 3. The community is largely bullish on the clinical and platform prospects, while some caution that efficacy and safety still need validation in larger trials; JPMorgans Overweight coverage has added to the discussion.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFis prolonged share-price decline is driving a frustrated, sharply divided discussion, with traders blaming past share offerings and insider sales, rising-rate concerns, and perceived short pressure. Bulls point to business growth and recent product developments, but many say those positives have not translated into stronger stock performance; others expect further downside ahead of Q3 earnings.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised 2026 revenue outlook, reflecting stronger demand for Amtagvi and Proleukin, is driving the sharp rally and renewed analyst optimism. Traders are debating whether heavy short covering is amplifying the move, while also watching for a pullback and upcoming lung-cancer data.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is drawing attention as its shares and the broader defense sector sell off despite elevated missile demand and a large backlog. Traders debate whether the weakness reflects sector rotation and budget or political concerns, while bullish voices point to replenishment needs and new defense contracts; the reasons for the decline remain disputed.

Goodyear Tire & Rubber Co. engages in the development, manufacture, distribution, and sale of tires. It operates through the following geographical segments: Americas, Europe, Middle East, and Africa, and Asia Pacific. The Americas segment is involved in the development, manufacture, distribution, and sale of tires and related products and services in North, Central, and South America. The Europe, Middle East, and Africa segment focuses on the development, manufacture, distribution, and sale of tires for automobiles, trucks, buses, aircraft, motorcycles, earthmoving, mining, and industrial equipment throughout Europe, the Middle East, and Africa. The Asia Pacific segment refers to the development, manufacture, distribution, and sales of tires for automobiles, trucks, buses, aircraft, farm, earthmoving, mining, and industrial equipment throughout the Asia Pacific region. The company was founded by Frank A. Seiberling on August 29, 1898 and is headquartered in Akron, OH.

Goodyear Tire & Rubber Co.

Traders are speculating about a possible buyout or take-private deal and a short squeeze, fueled by Goodyears depressed share price and sharp moves; no deal is confirmed. Others point to the companys debt, weak performance and exposure to oil costs as reasons for caution.

Robinhood GLD is a tokenized representation of SPDR Gold Shares (GLD) common stock, issued on Robinhood Chain, Robinhood's own blockchain built to bring tokenized real-world assets on-chain. Each token is designed to track the price of the underlying GLD share, giving holders on-chain price exposure to SPDR Gold Shares's stock. The token is freely transferable and composable across the Robinhood Chain ecosystem. It's part of Robinhood's broader initiative to expand access to tokenized U.S. equities via blockchain technology, alongside a wider lineup of tokenized stock tokens launching on the same network.

GoldCoin

Golds pullback is drawing attention as rising Treasury yields, a stronger dollar, and hawkish Fed expectations weigh on precious metals. Traders are split between buying the dip and waiting for a clearer bottom, while others expect further weakness if yields stay elevated.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Positive Phase 3 DAYBREAK results for Kodiaks experimental wet AMD treatments, including Zenkuda, drove a sharp rally and sparked short-squeeze chatter. Traders are split between optimism about the drugs potential and concerns that the surge may outrun the evidence given remaining FDA and commercialization hurdles, as well as the companys financing needs and possible dilution.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

MAGS is drawing attention as traders track a possible renewed breakout in the Magnificent Seven and its role in leading or supporting the broader market. Bulls point to mega-cap strength and rotation back toward the group, while skeptics cite narrow market breadth and doubts about AI spending returns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$MYNA is accepting claims for a $300K settlement to resolve allegations it misled investors about production delays, component shortages, and its ability to meet financial guidance for 2024. 
 
Even though the filing deadline has passed, if you bought $MYNA between June 20, 2024, and January 3, 2025, you still can file for payment here: https://11th.com/cases/mynaric-investor-suit?utm_source=stocktwits&amp;utm_medium=referral&amp;utm_campaign=stlm&amp;utm_content=10142025_1

Mynaric has reached a settlement with $MYNA investors over claims that it misled them about production delays, component shortages, and its ability to meet f...

11th.com

Mynaric ($MYNA) Investor Settlement

StockTwits Web

Mynaric ADS

 is accepting claims for a $300K settlement to resolve allegations it misled investors about production delays, component shortages, and its ability to meet financial guidance for 2024. 
 
Even though the filing deadline has passed, if you bought 

 between June 20, 2024, and January 3, 2025, you still can file for payment here: 